JP2011525363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011525363A5 JP2011525363A5 JP2011515200A JP2011515200A JP2011525363A5 JP 2011525363 A5 JP2011525363 A5 JP 2011525363A5 JP 2011515200 A JP2011515200 A JP 2011515200A JP 2011515200 A JP2011515200 A JP 2011515200A JP 2011525363 A5 JP2011525363 A5 JP 2011525363A5
- Authority
- JP
- Japan
- Prior art keywords
- modified
- complex
- vwf
- fviii
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010047303 von Willebrand Factor Proteins 0.000 claims 63
- 102100036537 von Willebrand factor Human genes 0.000 claims 63
- 229960001134 von willebrand factor Drugs 0.000 claims 63
- 108010054218 Factor VIII Proteins 0.000 claims 62
- 102000001690 Factor VIII Human genes 0.000 claims 62
- 229960000301 factor viii Drugs 0.000 claims 62
- 229920001184 polypeptide Polymers 0.000 claims 61
- 102000004196 processed proteins & peptides Human genes 0.000 claims 61
- 108090000765 processed proteins & peptides Proteins 0.000 claims 61
- 239000013598 vector Substances 0.000 claims 15
- 238000001727 in vivo Methods 0.000 claims 13
- 238000011084 recovery Methods 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- 239000013612 plasmid Substances 0.000 claims 12
- 102000040430 polynucleotide Human genes 0.000 claims 10
- 108091033319 polynucleotide Proteins 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 10
- 238000000034 method Methods 0.000 claims 8
- 210000004899 c-terminal region Anatomy 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 238000012986 modification Methods 0.000 claims 4
- 230000004048 modification Effects 0.000 claims 4
- 208000015294 blood coagulation disease Diseases 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 2
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 2
- 208000027276 Von Willebrand disease Diseases 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 230000002035 prolonged effect Effects 0.000 claims 2
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 claims 2
- 108010080865 Factor XII Proteins 0.000 claims 1
- 102000000429 Factor XII Human genes 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 208000031169 hemorrhagic disease Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08011429.1 | 2008-06-24 | ||
| EP08011429 | 2008-06-24 | ||
| PCT/EP2009/004549 WO2009156137A1 (en) | 2008-06-24 | 2009-06-24 | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011525363A JP2011525363A (ja) | 2011-09-22 |
| JP2011525363A5 true JP2011525363A5 (enExample) | 2012-07-26 |
| JP5832285B2 JP5832285B2 (ja) | 2015-12-16 |
Family
ID=40042814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011515200A Expired - Fee Related JP5832285B2 (ja) | 2008-06-24 | 2009-06-24 | 延長されたインビボ半減期を有する第ｖｉｉｉ因子、フォン・ヴィレブランド因子又はそれらの複合体 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8575104B2 (enExample) |
| EP (2) | EP2865760B1 (enExample) |
| JP (1) | JP5832285B2 (enExample) |
| KR (2) | KR101507718B1 (enExample) |
| CN (2) | CN102076855A (enExample) |
| AU (1) | AU2009262476C1 (enExample) |
| CA (1) | CA2728012C (enExample) |
| DK (2) | DK2865760T3 (enExample) |
| ES (2) | ES2531464T3 (enExample) |
| PL (1) | PL2291523T3 (enExample) |
| RU (1) | RU2528855C2 (enExample) |
| WO (1) | WO2009156137A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6263355A (ja) * | 1985-09-13 | 1987-03-20 | Hitachi Ltd | バツテリバツクアツプｒａｍのチエツク方法 |
| EP2865760B1 (en) | 2008-06-24 | 2017-10-11 | CSL Behring GmbH | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
| US8546548B2 (en) | 2009-05-27 | 2013-10-01 | Baxter International Inc. | Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use |
| AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| CA2771999A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor vii compositions and methods of making and using same |
| RU2579977C2 (ru) * | 2009-11-13 | 2016-04-10 | Грифольс Терапьютикс Инк. | СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ |
| EP2536753B1 (en) * | 2010-02-16 | 2017-12-20 | Novo Nordisk A/S | Factor viii molecules with reduced vwf binding |
| WO2011101284A1 (en) * | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Factor viii fusion protein |
| US9234192B2 (en) | 2010-02-16 | 2016-01-12 | Novo Nordisk A/S | Conjugated proteins |
| US8772462B2 (en) | 2010-05-26 | 2014-07-08 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
| CN103732244A (zh) * | 2011-06-10 | 2014-04-16 | 巴克斯特国际公司 | 通过施用重组vwf治疗凝血疾病 |
| HRP20191920T1 (hr) * | 2012-01-12 | 2020-01-10 | Bioverativ Therapeutics Inc. | Kimerni polipeptidi faktora viii i njihova uporaba |
| JP2015507929A (ja) * | 2012-02-14 | 2015-03-16 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 第Ｘａ因子阻害剤に対する組み換え拮抗剤を製作するためのプロセス |
| CN111548418A (zh) * | 2012-02-15 | 2020-08-18 | 比奥贝拉蒂治疗公司 | 因子viii组合物及其制备和使用方法 |
| US9458223B2 (en) | 2012-02-15 | 2016-10-04 | Csl Behring Gmbh | Von willebrand factor variants having improved factor VIII binding affinity |
| WO2013123457A1 (en) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| US20150080309A1 (en) | 2012-04-24 | 2015-03-19 | Nova Nordisk A/S | Compounds Suitable for Treatment of Haemophilia |
| ES2770501T3 (es) * | 2012-07-11 | 2020-07-01 | Bioverativ Therapeutics Inc | Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos |
| EP2796145B1 (en) * | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
| US10231993B2 (en) | 2013-06-27 | 2019-03-19 | University Of Washington Through Its Center For Commercialization | Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders |
| HK1223303A1 (zh) * | 2013-06-28 | 2017-07-28 | Bioverativ Therapeutics Inc. | 凝血酶可裂解连接子 |
| KR20230007555A (ko) * | 2013-06-28 | 2023-01-12 | 바이오버라티브 테라퓨틱스 인크. | Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도 |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| ES2693380T3 (es) | 2013-11-08 | 2018-12-11 | Csl Limited | Nuevo método para concentrar el factor de von Willebrand o complejos de este |
| EA201691111A1 (ru) | 2014-01-10 | 2017-01-30 | Байоджен Ма Инк. | Химерные белки фактора viii и их применение |
| EP3158055B1 (en) | 2014-06-13 | 2019-09-11 | CSL Limited | Improved production of recombinant von willebrand factor in a bioreactor |
| DE102014011653A1 (de) * | 2014-06-20 | 2015-12-24 | Ulrich Loos | Nachweis von Autoantikörpern gegen den TSH-Rezeptor |
| DK3164150T3 (da) * | 2014-07-02 | 2021-02-08 | CSL Behring Lengnau AG | Modificeret von willebrand-faktor |
| US10626164B2 (en) | 2014-07-25 | 2020-04-21 | Csl Limited | Purification of VWF |
| KR102554850B1 (ko) * | 2015-02-06 | 2023-07-13 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도 |
| SG11201706659WA (en) | 2015-03-06 | 2017-09-28 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
| CA2986625A1 (en) | 2015-05-22 | 2016-12-01 | Csl Behring Recombinant Facility Ag | Methods for preparing modified von willebrand factor |
| CA2986626A1 (en) | 2015-05-22 | 2016-12-01 | Csl Behring Recombinant Facility Ag | Truncated von willebrand factor polypeptides for treating hemophilia |
| UA126016C2 (uk) | 2015-08-03 | 2022-08-03 | Біовератів Терапеутікс Інк. | Злитий білок фактора іх |
| WO2017112895A1 (en) * | 2015-12-23 | 2017-06-29 | Haplomics, Inc. | F8 gene repair |
| SG11201805494WA (en) * | 2016-01-07 | 2018-07-30 | Csl Behring Recombinant Facility Ag | Mutated von willebrand factor |
| AU2017204955B2 (en) | 2016-01-07 | 2021-04-01 | CSL Behring Lengnau AG | Mutated truncated von Willebrand Factor |
| US12171808B2 (en) * | 2016-05-20 | 2024-12-24 | Octapharma Ag | Glycosylated VWF fusion proteins with improved pharmacokinetics |
| JP6877469B2 (ja) * | 2016-06-24 | 2021-05-26 | モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ | Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用 |
| JP2020504082A (ja) | 2016-11-11 | 2020-02-06 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド |
| DK3538133T3 (da) | 2016-11-11 | 2021-04-19 | CSL Behring Lengnau AG | Trunkeret von willebrand faktor polypeptider til behandling af hæmofili |
| KR20190090827A (ko) | 2016-12-02 | 2019-08-02 | 바이오버라티브 테라퓨틱스 인크. | 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법 |
| DK3641800T5 (da) | 2017-06-22 | 2024-08-26 | CSL Behring Lengnau AG | Modulation af fviii immunogenicitet ved trunkeret vwf |
| JP7326246B2 (ja) | 2017-07-07 | 2023-08-15 | 武田薬品工業株式会社 | 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法 |
| FI3648788T5 (fi) | 2017-07-07 | 2024-09-09 | Takeda Pharmaceuticals Co | Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää |
| EP3672644A1 (en) * | 2017-08-23 | 2020-07-01 | CSL Behring GmbH | Method for virus filtration of von willebrand factor |
| KR102914074B1 (ko) | 2018-05-18 | 2026-01-16 | 바이오버라티브 테라퓨틱스 인크. | A형 혈우병의 치료 방법 |
| EP3897831A1 (en) * | 2018-12-23 | 2021-10-27 | CSL Behring LLC | Donor t-cells with kill switch |
| EA202192140A1 (ru) | 2019-02-01 | 2021-12-15 | Такеда Фармасьютикал Компани Лимитед | СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ) |
| CN111592591B (zh) * | 2020-06-17 | 2021-12-14 | 博雅生物制药集团股份有限公司 | 一种人血管性血友病因子/人凝血因子ⅷ复合物的制备方法及产物和应用 |
| CN117720671B (zh) * | 2024-01-30 | 2024-06-14 | 南通大学 | 具有自组装性能的重复结构单元重组蛋白ⅠAⅠB-ⅠAⅠBrQTY及应用 |
| CN121319224B (zh) * | 2025-12-18 | 2026-04-28 | 山东艾科达生物科技有限公司 | 一种检测adamts13活性的蛋白组合及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| FR2673632A1 (fr) | 1991-03-08 | 1992-09-11 | Lille Transfusion Sanguine | Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique. |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5364771A (en) * | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
| DE4435485C1 (de) | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| CA2205572A1 (en) | 1994-12-12 | 1996-06-20 | Beth Israel Hospital Association | Chimeric cytokines and uses thereof |
| AU6455896A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| AT403764B (de) * | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
| PT1754718E (pt) | 1996-04-24 | 2011-07-13 | Univ Michigan | Factor viii resistente à inactivação |
| US20040092442A1 (en) | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
| US6103077A (en) * | 1998-01-02 | 2000-08-15 | De Nora S.P.A. | Structures and methods of manufacture for gas diffusion electrodes and electrode components |
| CA2329768C (en) | 1998-04-27 | 2008-06-10 | Opperbas Holding B.V. | Pharmaceutical composition comprising factor viii and neutral liposomes |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6926898B2 (en) * | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1148063A1 (de) | 2000-04-18 | 2001-10-24 | Octapharma AG | Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung |
| US7615622B2 (en) | 2001-01-12 | 2009-11-10 | University Of Maryland, Baltimore | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII |
| EP1421539B1 (en) | 2001-06-14 | 2009-10-28 | The Scripps Research Institute | Stabilized factor viii with engineered disulfide bonds |
| AU2003210806A1 (en) | 2002-03-05 | 2003-09-22 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| US8586538B2 (en) | 2002-04-29 | 2013-11-19 | Stichting Sanquin Bloedvoorziening | Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII |
| KR20140148502A (ko) * | 2002-12-09 | 2014-12-31 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
| EP1444986A1 (en) * | 2003-02-07 | 2004-08-11 | Aventis Behring GmbH | Pharmaceutical preparation for the improved treatment of blood-clotting disorders |
| EP1596887B1 (en) | 2003-02-26 | 2022-03-23 | Nektar Therapeutics | Polymer-factor viii moiety conjugates |
| SI1624891T2 (sl) * | 2003-05-06 | 2013-09-30 | Biogen Idec Hemophilia Inc. | Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| ES2371072T3 (es) | 2003-06-12 | 2011-12-27 | Eli Lilly And Company | Proteínas de fusión análogas de glp-1. |
| EP1502921A1 (en) * | 2003-07-29 | 2005-02-02 | ZLB Behring GmbH | Recombinant mutated human factor VIII (FVIII) with improved stability |
| AU2004271200A1 (en) * | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| EP1699821B1 (en) | 2003-12-31 | 2012-06-20 | Merck Patent GmbH | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| DK2371856T3 (en) | 2004-11-12 | 2022-08-08 | Bayer Healthcare Llc | Site-directed modifikation af FVIII |
| AU2005322067B8 (en) | 2004-12-27 | 2012-07-26 | Takeda Pharmaceutical Company Limited | Polymer-von Willebrand factor-conjugates |
| KR20080007226A (ko) | 2005-04-14 | 2008-01-17 | 체에스엘 베링 게엠베하 | 증가된 안정성을 가진 변형된 응고 인자 ⅷ 및 이의 유도체 |
| EP1958648A4 (en) | 2005-10-28 | 2009-12-30 | Dnavec Corp | THERAPEUTIC PROCESS FOR BLOOD CLEANING DISORDER |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| WO2007126808A1 (en) | 2006-03-31 | 2007-11-08 | Baxter International Inc | Pegylated factor viii |
| EP1867660A1 (en) * | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| WO2007144173A1 (en) | 2006-06-14 | 2007-12-21 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| EP2865760B1 (en) | 2008-06-24 | 2017-10-11 | CSL Behring GmbH | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
| US9402754B2 (en) * | 2010-05-18 | 2016-08-02 | Abbott Cardiovascular Systems, Inc. | Expandable endoprostheses, systems, and methods for treating a bifurcated lumen |
| HRP20191920T1 (hr) | 2012-01-12 | 2020-01-10 | Bioverativ Therapeutics Inc. | Kimerni polipeptidi faktora viii i njihova uporaba |
| US20150080309A1 (en) | 2012-04-24 | 2015-03-19 | Nova Nordisk A/S | Compounds Suitable for Treatment of Haemophilia |
-
2009
- 2009-06-24 EP EP14192277.3A patent/EP2865760B1/en not_active Not-in-force
- 2009-06-24 DK DK14192277.3T patent/DK2865760T3/en active
- 2009-06-24 ES ES09768986.3T patent/ES2531464T3/es active Active
- 2009-06-24 EP EP09768986.3A patent/EP2291523B1/en active Active
- 2009-06-24 CA CA2728012A patent/CA2728012C/en not_active Expired - Fee Related
- 2009-06-24 CN CN200980123818XA patent/CN102076855A/zh active Pending
- 2009-06-24 RU RU2011102366/10A patent/RU2528855C2/ru active
- 2009-06-24 PL PL09768986T patent/PL2291523T3/pl unknown
- 2009-06-24 AU AU2009262476A patent/AU2009262476C1/en not_active Ceased
- 2009-06-24 KR KR1020117001530A patent/KR101507718B1/ko not_active Expired - Fee Related
- 2009-06-24 JP JP2011515200A patent/JP5832285B2/ja not_active Expired - Fee Related
- 2009-06-24 CN CN201310596839.1A patent/CN103739712B/zh not_active Expired - Fee Related
- 2009-06-24 ES ES14192277.3T patent/ES2654336T3/es active Active
- 2009-06-24 WO PCT/EP2009/004549 patent/WO2009156137A1/en not_active Ceased
- 2009-06-24 DK DK09768986T patent/DK2291523T3/en active
- 2009-06-24 KR KR1020147018123A patent/KR101648734B1/ko not_active Expired - Fee Related
- 2009-06-24 US US13/000,938 patent/US8575104B2/en not_active Expired - Fee Related
-
2013
- 2013-09-17 US US14/028,869 patent/US9290561B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2685611T3 (es) | Vector VAA8 mejorado con una actividad funcional aumentada y métodos de utilización del mismo | |
| JP5902679B2 (ja) | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン | |
| RU2011102366A (ru) | Фактор viii, фактор виллебранда или их комплексы с удлиненным полупериодом существования in vivo | |
| ES2329334T3 (es) | Formas multimericas de ligandos de la superfamilia de tnf. | |
| WO2024109611A1 (zh) | 突变型呼吸道合胞病毒融合前f蛋白及其应用 | |
| JP5291671B2 (ja) | 融合タンパク質の免疫原性の低減 | |
| JP5077924B2 (ja) | 分泌された三量体受容体類似体及び生物学的活性融合タンパク質を製造するための方法及び組成物 | |
| JP2021003120A (ja) | 止血疾患を治療するための変異因子ｖｉｉｉのゲノム組込及び発現のための改良された発現カセット | |
| JP2015518479A5 (enExample) | ||
| WO2010105573A1 (zh) | 抗血管新生融合蛋白 | |
| JP2015500811A5 (enExample) | ||
| WO2023030444A1 (zh) | Glp-1/gip双靶多肽、融合蛋白及其应用 | |
| JP2017529059A5 (enExample) | ||
| TW200808824A (en) | Binding molecules 3 | |
| CN104039833A (zh) | 针对hpv的疫苗 | |
| JP2018538003A5 (enExample) | ||
| JP2017529326A5 (enExample) | ||
| CA2261562A1 (en) | Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses | |
| JP2014510519A5 (enExample) | ||
| CN109320615A (zh) | 靶向新型bcma的嵌合抗原受体及其用途 | |
| CN103965362B (zh) | 一种可使t细胞趋向肿瘤部位的嵌合趋化因子受体 | |
| JP2022517267A (ja) | 血友病ａの遺伝子療法のための発現が上昇した組換えｆｖｉｉｉバリアントをコードするウイルスベクター | |
| JP2014517690A5 (enExample) | ||
| JP2023548838A5 (enExample) | ||
| TWI250164B (en) | Highly purified cytokine activating factor and methods of use |